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Abstract
Uterine leiomyosarcomas (ULMSs) are aggressive smooth muscle tumors associated with
poor clinical outcome. Despite previous cytogenetic and molecular studies, their molecular
background has remained elusive. To examine somatic variation in ULMS, we performed
exome sequencing on 19 tumors. Altogether, 43 genes were mutated in at least two
ULMSs. Most frequently mutated genes included tumor protein P53 (TP53; 6/19; 33%),
alpha thalassemia/mental retardation syndrome X-linked (ATRX; 5/19; 26%), andmediator
complex subunit 12 (MED12; 4/19; 21%). Unlike ATRXmutations, both TP53 andMED12
alterations have repeatedly been associated with ULMSs. All the observed ATRX alter-
ations were either nonsense or frameshift mutations. ATRX protein levels were reliably ana-
lyzed by immunohistochemistry in altogether 44 ULMSs, and the majority of tumors (23/44;
52%) showed clearly reduced expression. Loss of ATRX expression has been associated
with alternative lengthening of telomeres (ALT), and thus the telomere length was analyzed
with telomere-specific fluorescence in situ hybridization. The ALT phenotype was confirmed
in all ULMSs showing diminished ATRX expression. Exome data also revealed one non-
sense mutation in death-domain associated protein (DAXX), another gene previously asso-
ciated with ALT, and the tumor showed ALT positivity. In conclusion, exome sequencing
revealed that TP53, ATRX, andMED12 are frequently mutated in ULMSs. ALT phenotype
was commonly seen in tumors, indicating that ATR inhibitors, which were recently sug-
gested as possible new drugs for ATRX-deficient tumors, could provide a potential novel
therapeutic option for ULMS.
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Author Summary
Uterine leiomyosarcomas are rare, malignant smooth muscle tumors with a poor 5-year
survival and high recurrence rate. They account for 1–2% of all uterine malignancies with
an estimated incidence of 0.4/100,000 women per year. The symptoms and signs of this
tumor type widely overlap with those of common benign uterine leiomyomas, making
early diagnosis of uterine leiomyosarcomas difficult. Currently, the diagnosis of these
tumors is often incidental and postoperative. Despite previous cytogenetic and molecular
studies, their molecular background has remained elusive. Identification of novel molecu-
lar genetic characteristics in uterine leiomyosarcomas is clinically relevant to further
improve the diagnosis and prognosis of the patients. Here, we performed exome sequenc-
ing on 19 tumors, revealing frequent mutations in TP53, ATRX, andMED12. The discov-
ery of frequent inactivating ATRXmutations provides a potential novel therapeutic target
for uterine leiomyosarcomas.
Introduction
Uterine leiomyosarcoma (ULMS) is a rare, highly malignant tumor that originates from the
smooth muscle layer of the uterus, the myometrium. It is the most common subtype of uterine
sarcoma and accounts for 1–2% of all uterine malignancies with an estimated incidence of 0.4/
100,000 women per year [1,2]. The majority of ULMSs occur in women over 50 years of age
typically causing symptoms such as abnormal vaginal bleeding, palpable pelvic mass, and
abdominal pain. These symptoms greatly resemble those of common benign uterine leio-
myoma, making early diagnosis of ULMS difficult. Surgical resection is the primary treatment
option, while the use of adjuvant therapies varies widely. ULMS show low sensitivity to both
chemotherapy and radiation therapy [3,4]. In most cases, the diagnosis is made histologically
after the surgery, and even then, the clinical course of ULMS is difficult to predict. Currently,
the most prominent prognostic factors include stage, age, and tumor size [5–7]. The 5-year
overall survival has remained<50% due to a high recurrence rate (53–71%) and metastatic
capacity [6,8].
Most ULMSs are aneuploid with both complex numerical and structural chromosomal
aberrations [9]. Albeit no consistent structural aberrations have been identified, abnormalities
affecting chromosomal regions 1p, 10q, 13q, and 14q have been observed in multiple cases
[10]. So far, only a few genes have been associated with this tumor type, including tumor pro-
tein P53 (TP53), RB1,MDM2, CDKN2A, and KIT [9,11]. These are all common cancer genes
not specific for smooth muscle malignancies and the exact molecular mechanisms underlying
ULMS tumorigenesis remain elusive.
During the last decade, next-generation sequencing technologies have increasingly provided
genome-wide data on somatic landscapes in various cancer types enabling the discovery of
novel cancer genes and mechanisms with important prognostic and therapeutic implications
[12]. Here, we performed exome sequencing on 19 ULMSs to further elucidate the molecular
etiology of these tumors, identifying frequent mutations in TP53, alpha thalassemia/mental
retardation syndrome X-linked (ATRX), andmediator complex subunit 12 (MED12). This is the
first description of high-throughput sequencing on ULMSs.
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Results
Recurrently mutated genes observed in exome sequencing
We performed exome sequencing on genomic DNA of 19 formalin-fixed paraffin-embedded
(FFPE) ULMSs. The average coverage of captured exonic regions reached a mean depth of 21x
and 92% of the captured regions had a minimum coverage of four reads (S1 Table). After filter-
ing the exome sequencing data, we observed a mean of 373 somatic mutations per tumor
(range 240–779). The majority of mutations in each tumor specimen represented single-nucle-
otide variations (*88%; range 81–95%), while deletions accounted for*9% (range 4–15%)
and insertions*3% (range 1–7%) (S1 Table). Two tumors, LMS49 and LMS51, harbored
more mutations than other ULMSs, but the mutation spectrum followed the common pattern.
In the exome sequencing data analysis, we focused on genes that were mutated in at least
two tumors. This resulted in a list of 43 genes (S2 Table). The majority of these genes (37/43;
86%) were mutated in two tumors, while six genes, TP53, ATRX,MED12, fibrous sheath inter-
acting protein 2 (FSIP2), ATP-binding cassette, sub-family A (ABC1),member 13 (ABCA13),
and ankyrin repeat domain 26 (ANKRD26), had mutations in three or more tumors (Fig 1).
The most frequently mutated gene was TP53, which was mutated in six tumors (6/19; 32%) (S1
Fig). Two mutations were nonsense mutations creating a premature stop-codon and four were
missense alterations; all missense changes were predicted pathogenic by two independent in sil-
ico tools (S2 Table). All the observed TP53mutations have been reported as somatic mutations
in the COSMIC-database.
The second most commonly mutated gene was ATRX, which was mutated in five tumors
(5/19; 26%) (S1 Fig). The total number of mutations was six as one tumor (LMS71) contained
two distinct mutations. All mutations were either nonsense mutations or small frameshift
insertions or deletions, and were thus predicted to result in a truncated protein product. As
ATRXmutations have been associated with alternative lengthening of telomeres (ALT), we
specifically searched the exome sequencing data for possible mutations in death-domain associ-
ated protein (DAXX), as also these mutations have been associated with the ALT phenotype
[13,14]. Indeed, one ULMS (LMS61) had a mutation in DAXX. This mutation was a nonsense
mutation (Glu650Stop) most likely leading to a truncated or unstable protein product.
Fig 1. Most frequently mutated genes in 19 ULMSs studied by exome-sequencing. Five tumors did not have mutations in any of the six genes listed.
doi:10.1371/journal.pgen.1005850.g001
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Four mutations (4/19; 21%) were observed inMED12 (S1 Fig). All these were missense
changes affecting amino acids Gly44 (3 mutations) or Leu36 (1 mutation), which have previ-
ously been reported as mutational hotspots in uterine leiomyomas [15]. All mutations were
predicted to have a deleterious effect on protein function (S2 Table). NeitherMED12, TP53,
nor ATRXmutations were mutually exclusive (Fig 1).
Alterations in FSIP2 (4/19; 21%), ABCA13 (3/19; 16%), and ANKRD26 (3/19; 16%) all rep-
resented missense changes that scattered along the gene lengths. Two tumors had the same
Met487Ile substitution in ANKRD26. One alteration (Gln581Leu) in FSIP2 and all changes in
ABCA13 were predicted pathogenic by both Polyphen-2 and SIFT, whereas none of the other
variants were predicted damaging by both in silico tools.
Aberrant TP53, ATRX, and DAXX expression in ULMS
We evaluated the protein expression levels of TP53, ATRX, and DAXX in the 19 exome-
sequenced ULMSs by immunohistochemistry and validated the results in a larger set of 33
additional tumors (S2 Fig and S3 Table). DAXX immunostaining was successful in all 52
tumors and interpretable results for TP53 and ATRX were obtained from 50 and 44 tumors
(50/52, 96%; 44/52, 85%). Aberrant TP53 expression was observed in 33 out of 50 ULMSs
(66%) (S3 Table). Twenty-three out of 44 successfully analyzed ULMSs (52%) showed loss of
nuclear ATRX expression, including all immunohistochemically successful ATRXmutation-
positive tumors. Clearly diminished DAXX expression was present in only one ULMS (1/52,
2%) (Fig 2A and 2C): a tumor with the nonsense mutation (S3 Table).
Fluorescence in situ hybridization shows alternative lengthening of
telomeres
Telomere-specific fluorescence in situ hybridization (FISH) was carried out to assess the poten-
tial effect of ATRX and DAXXmutations on telomere length (Fig 2B and 2D). Twelve out of 19
exome-sequenced ULMSs (63%) were ALT-positive (S3 Table). This included four out of five
ATRXmutation-positive tumors (80%) as well as the one DAXXmutation-positive tumor.
Also seven out of 13 cases (54%) without detectable ATRX or DAXXmutations showed ALT
positivity. Loss of ATRX or DAXX expression seems to correlate very well with the ALT
phenotype.
The effect of aberrant TP53 and ATRX expression on patient survival
Kaplan-Meier survival curves were generated to study the association between TP53 and
ATRX expression and overall survival time. The median overall survival time for all patients
was 65 months (95% confidence interval 31.7–98.3 months). Only the number of Stage I
tumors was large enough for the analyses. Neither aberrant TP53 or ATRX expression associ-
ated with poor survival (P = 0.261, P = 0.127) (Fig 3). Of note, TP53 and ATRX expression sta-
tuses correlated with each other (P = 0.005).
Discussion
In this study, we examined somatic variation in 19 ULMSs by exome sequencing. We focused
on genes, which were mutated in at least two tumors; altogether 43 such genes were identified.
The most frequently mutated genes included TP53, ATRX,MED12, FSIP2, ABCA13, and
ANKRD26. TP53 was the most commonly mutated gene with 32% of the tumors harboring
mutations. Alterations in TP53 have been previously implicated in leiomyosarcomas and sug-
gested to play a role in leiomyosarcoma pathogenesis [16–18]. In this study, most mutations
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Fig 2. Representative images of ATRX and DAXX expression and ALT phenotype in ULMS. ATRX-mutated ULMS showing loss of ATRX expression
(A) and positive ALT phenotype (B). Large, abnormally bright telomere FISH signals (red) are indicative of ALT. DAXX-mutated ULMS with reduced DAXX
expression (C) and positive ALT phenotype (D). Immunohistochemical stainings are shown with 10×20 magnification and FISH stainings with 10×63
magnification.
doi:10.1371/journal.pgen.1005850.g002
Fig 3. Overall survival of patients with Stage I ULMS according to TP53 and ATRX expression status.
(A) TP53 expression (n = 29) and (B) ATRX expression (n = 26).
doi:10.1371/journal.pgen.1005850.g003
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(67%) were missense changes located in exons 4–8. This is in line with previous studies, where
the majority of mutations have been missense mutations in exons 5–8, the most highly con-
served region of the gene [9,17,19]. These mutations are known to alter the protein structure,
inhibit its tumor suppressor function, and result in its prolonged half-life. Immunohistochemi-
cal analysis including 50 ULMSs confirmed altered expression in the majority of tumors,
highlighting the role of TP53 in ULMS development.
ATRX was the second most frequently mutated gene with mutations observed in five tumors
(26%). All mutations were either nonsense or frameshift alterations most likely leading to a
truncated protein product. Loss of ATRX expression has been reported in leiomyosarcomas of
various sites [20–22] and a recent meeting abstract on ULMSs reported genomic alterations of
this gene in 32% (8/25) of the studied tumors, supporting our findings [23]. We successfully
analyzed ATRX protein levels in 44 ULMSs and showed that 52% of the tumors, including all
reliably analyzed mutation-positive lesions, had clearly reduced expression. ATRX encodes a
transcriptional regulator that contains an ATPase/helicase domain, and is thus a member of
the SWI/SNF family of chromatin remodelling proteins. Loss of ATRX expression has been
associated with ALT [13,24], which prompted us to analyze the telomeres with telomere-spe-
cific FISH. The ALT phenotype was confirmed in all ULMSs with diminished ATRX expres-
sion. Some exome-sequenced tumors with reduced ATRX expression and ALT positivity did
not show ATRXmutations, suggesting that there are regulatory or larger structural alterations
undetectable by exome sequencing, or that the quality of FFPE samples was inadequate to
reveal the underlying mutation. Interestingly, the only ULMS with two ATRXmutations did
not show ALT.
ATRX is known to functionally cooperate with DAXX and DAXXmutations have been
associated with ALT [13,14]. We therefore scrutinized the exome data for possible DAXX
mutations. One nonsense mutation was identified, and FISH confirmed the ALT phenotype.
Overall, these results show that ALT is very common in ULMS and that in addition to ATRX,
also DAXXmutations contribute to the phenotype. Importantly, ALT was recently suggested
to render cancer cells hypersensitive to ATR inhibitors [25]. These inhibitors might provide a
novel treatment for ULMS, in which chemotherapeutic options have thus far been limited.
MED12 was mutated in four ULMSs (21%). All mutations were in exon 2, which is a known
mutational hotspot inMED12. These mutations were first observed in uterine leiomyomas
[15], and subsequently they have been identified in other tumor types [26]. Previous screening
studies have reported recurrentMED12mutations also in ULMS with similar frequencies as
observed here [26]. It may be that a subset of ULMSs arises through a leiomyoma precursor, or
alternativelyMED12mutations may provide growth advantage to ULMSs. MED12 is part of a
multi-protein complex Mediator, which plays a key role in global transcription regulation in
eukaryotic cells [27]. Based on our results,MED12mutations can co-occur with TP53 and
ATRXmutations.
FSIP2, ABCA13, and ANKRD26 were mutated in at least three tumors and additional 37
genes had mutations in two tumors. Most alterations were missense changes and gave either
neutral or controversial results in in silico predictions. The possible role of these genes in
ULMS development cannot be directly assessed as in addition of providing growth advantage
to the cell, the observed alterations may represent rare germline polymorphisms or passenger
mutations with no functional significance.
Although aberrant expression of both TP53 and ATRX in Stage I ULMSs, the only group of
tumors large enough for the analyses, did not associate with poor overall survival, a trend
toward poorer survival was seen in the patients. The limited number of samples in the survival
analyses and the observation that expression statuses were associated with each other makes it
difficult to draw conclusions regarding prognostic implications of TP53 or ATRX expression
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levels. In general, TP53 alterations are the most common genetic changes in human cancers
and they are particularly associated with an aggressive phenotype. Recently, loss of ATRX
expression was associated with poor clinical outcome in ULMS [21,22]. Larger sample series
with information on both TP53 and ATRX are required to confirm these findings.
ULMSs are rare and aggressive cancers. In most cases the diagnosis is made only at surgery,
and many patients thus present with an advanced disease. Here, we have utilized exome
sequencing and identified several recurrently mutated genes, including TP53, ATRX, and
MED12. WhileMED12mutations are the most common alterations in benign conventional
leiomyomas, TP53 or ATRXmutations have not been observed in these tumors. Specifically,
identification of inactivating ATRXmutations and their association with the ALT phenotype
in the substantial proportion of tumors may be translatable into clinical practice should the
suggested effect of ATR inhibitors prove effective.
Materials and Methods
Ethics statement
This study was approved by the appropriate ethics review board of Hospital District of Helsinki
and Uusimaa, Finland (408/13/03/03/2009).
Patient samples
Fifty-two archival FFPE ULMS tissue samples were derived from the Department of Pathology,
Hospital District of Helsinki and Uusimaa, Finland, according to Finnish laws and regulations
by permission of the director of the respective health care unit. These specimens represented
diagnostic ULMS samples collected during surgery in 1985–2013. Simultaneously with the
sample collection, clinical data were obtained for these cases (Table 1) after which the samples
were anonymized for the study. Nineteen ULMSs (diagnosis 2003–2013) entered exome
sequencing, while the remaining 33 tumors were available on a tissue microarray for
immunohistochemistry.
Histological evaluation
Before exome sequencing, hematoxylin-eosin-stained sections from each specimen were re-
evaluated by a pathologist (RB) and verified as ULMSs according to the WHO criteria [28].
Tumor percentage was90% in all samples.
Exome sequencing
Genomic DNA was extracted with a standard phenol-chloroform method. Sample libraries
were prepared using NEBNext DNA Library Prep Reagent Set for Illumina (New England Bio-
labs Ltd. catalog# E6000) and subjected to exome capture with NimbleGen SeqCap EZ System
(Roche NimbleGen). Paired-end short read sequencing was performed with HiSeq 2000 (Illu-
mina Inc.) at Karolinska Institutet, Sweden.
Somatic variant calling
Read mapping and somatic variant calling were carried out as previously described [29]. Addi-
tionally, single duplicate reads were removed with an in-house script.
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Table 1. Clinical data of 52 ULMSs.
Case
ID
Age at
diagnosis
Primary
stage
Tumor size
(cm)
Tumor
necrosis
Mitotic index/
10 HPF
Atypia
(/3)
Metastasis Patient
status
Follow-up time
(months)
Exome-sequenced
ULMSs
LMS34 81 IC 7 + 5 2 + AWD 67
LMS35 63 IIB >10 + 10 2 + DOD 23
LMS37 67 IIIB 5 + 10 3 + DOD 18
LMS40 56 IB 6 - >20 2 - NED 53
LMS42 66 N/A 15 + 50 2 + DOD 18
LMS45 53 IA 3.5 - >20 2 - NED 32
LMS46 50 IC 12 + >20 3 - NED 14
LMS49 56 N/A 6.5 + >20 3 + DOD 41
LMS51 58 IB 30 + N/A 3 + AWD 44
LMS53 69 IC 15 + 16 3 - alive 80
LMS54 76 N/A 6 - >20 1 + DOD 17
LMS55 56 N/A 1.5 + >20 3 - NED 97
LMS59 59 IVB 14 + 14 2 + DOD 15
LMS61 54 I N/A + 33 2 + DOD 16
LMS66 52 IB 7 + 30 2 - NED 19
LMS68 48 N/A >10 N/A >10 3 + DOD 90
LMS71 72 IC 11 - >20 2 - deceaseda 40
LMS72 28 I 8 + 14 1 - NED 101
LMS75 75 N/A 7 - 30 2 - DOD 50
ULMSs on tissue
microarray
LMS1 69 IIIA N/A N/A N/A N/A + DOD 72
LMS2 44 IC 5 N/A N/A N/A + AWD 271
LMS3 52 IC 20 N/A 5 N/A + DOD 64
LMS4 72 IC N/A N/A N/A N/A + DOD 40
LMS5 41 IA N/A N/A 10 N/A + NED 279
LMS6 53 IB 12 N/A N/A N/A - NED 242
LMS7 77 IC 20 N/A N/A N/A + DOD 18
LMS8 77 IC N/A N/A N/A N/A - deceaseda 82
LMS9 57 N/A N/A N/A N/A N/A + DOD 142
LMS10 42 III 5 N/A 8 N/A + NED 225
LMS11 58 I 4 N/A N/A N/A - NED 199
LMS12 71 IIIA 20 N/A 20 N/A - DOD 6
LMS13 48 IIIA N/A N/A N/A N/A + DOD 8
LMS14 64 IVB 5 N/A N/A N/A - DOD 5
LMS15 64 IIIA 8 N/A 16 N/A + DOD 65
LMS16 69 IIIA N/A N/A N/A N/A - DOD 122
LMS17 34 IC 4 N/A 10 N/A - NED 194
LMS18 64 IC 10 N/A 5 N/A - deceaseda 21
LMS19 57 N/A 20 N/A N/A N/A + DOD 26
LMS20 81 IC 14 N/A N/A N/A - DOD 4
LMS21 59 IVA N/A N/A N/A N/A + DOD 14
LMS22 70 IC N/A N/A N/A N/A + DOD 10
LMS23 49 IC 10 N/A N/A N/A - NED 272
LMS24 49 IC 6 N/A N/A N/A - NED 166
(Continued)
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Variant identification
Exome data was analyzed with an in-house analysis and visualization tool RikuRator. The
requirements to call a variant included a minimum coverage of six reads and the mutated allele
to be present in at least 20% of the reads. The Genome Analysis Toolkit (GATK) quality score
of variants was required to be 25 or above. Both exonic regions and sequences within three
base pairs of the exon-intron boundaries were included in the study. Synonymous changes,
variants present in the dbSNP database (release 138), and variants in Exome Aggregation Con-
sortium Server with a frequency over 0.1% were disregarded. To remove other potential germ-
line variants, the exome data was filtered against data from 2315 Finnish controls (93
individuals from the 1000 Genomes Project, 1941 individuals from The Sequencing Initiative
Suomi (SISu) (http://www.sisu.fimm.fi), and 281 in-house control exomes or genomes).
Recently, it has been estimated that about 400 control samples remove germline variation (sin-
gle-nucleotide variants and indels) from a tumor sample at least as efficiently as the matched
normal sample [30]. Lastly, all the remaining variants were individually visualized with Rikura-
tor to exclude those only present in the same direction reads as likely artifacts. The functional
effects of the variants were predicted by two independent in silico tools: SIFT (http://sift.jcvi.
org/) and Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/).
Direct sequencing
All candidate variants in genes mutated in at least three tumors were validated by direct
sequencing. Oligonucleotide primers were designed with Primer3Plus software (http://www.
bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) (S4 Table). PCR products were
sequenced directly utilizing Big Dye Terminator v.3.1 sequencing chemistry (Applied Biosys-
tems) on an ABI3730 Automatic DNA Sequencer.
Immunohistochemistry
TP53, ATRX, and DAXX immunolabeling was performed on FFPE sections of all 19 exome-
sequenced ULMSs and on a tissue microarray containing 33 additional tumors. For TP53,
immunostaining was performed as previously described [31]. For ATRX and DAXX, heat-
induced antigen retrieval was carried out in a microwave using citrate buffer (pH 6.0) for 20
min. Endogenous peroxidase blocking was followed by overnight incubation with the primary
Table 1. (Continued)
Case
ID
Age at
diagnosis
Primary
stage
Tumor size
(cm)
Tumor
necrosis
Mitotic index/
10 HPF
Atypia
(/3)
Metastasis Patient
status
Follow-up time
(months)
LMS25 38 IC 4 N/A N/A N/A - NED 211
LMS27 62 IIB 10 N/A 10 N/A + DOD 61
LMS28 52 IC N/A N/A 20 N/A - NED 199
LMS29 42 IC 7 N/A N/A N/A - NED 213
LMS30 60 IIB 15 N/A N/A N/A + DOD 11
LMS31 40 IC 9 N/A N/A N/A + DOD 52
LMS57 81 IVB 15 + >20 3 + DOD 1
LMS62 56 IB 4 - 10 2 - NED 140
LMS64 54 I 9 - 15 3 + NED 134
a cause of death other than ULMS
HPF, high power ﬁeld; N/A, not available; DOD, died of disease; NED, no evidence of disease; AWD, alive with disease
doi:10.1371/journal.pgen.1005850.t001
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antibody at 4°C (anti-ATRX 1:500 dilution, Sigma-Aldrich catalog# HPA001906; anti-DAXX
1:500 dilution, Sigma-Aldrich catalog# HPA008736). The primary antibody was detected with
DAB Plus Substrate System (Thermo Fisher Scientific catalog# TA-060-HDX). Immunohisto-
chemical scoring was assessed by a pathologist (RB). Only nuclear labeling of the proteins was
evaluated. The loss of nuclear staining in tumor cells together with retained expression in non-
neoplastic cells (endothelial or inflammatory cells) was considered loss of expression. The scor-
ing was done without knowledge of the clinical outcome data.
Telomere-specific FISH and microscopy
Detection of large, abnormally intense, intra-nuclear telomere DNA aggregates via telomere-
specific FISH is considered the most sensitive and specific marker for identifying ALT pheno-
type in fixed tissue samples [13].
FFPE sections were deparaffinized at room temperature with xylene (3x10 min) and 100%
EtOH (2x10 min) and air-dried. Subsequently, the slides were rinsed in phosphate-buffered
saline (PBS) at 37°C (2x5 min) followed by RNAse A treatment (Sigma-Aldrich catalog#
R4642) at 37°C for an hour. After a series of washes at room temperature with saline-sodium
citrate (pH 7.0; 3x5 min) and deionized water (2x5 min), the slides were digested with Digest
All 3-pepsin (Invitrogen/Life Technologies catalog# 00–3009) at 37°C for 10 min and rinsed
with PBS at room temperature (2x5 min). Next, the slides were dehydrated and hybridized
with Cy3-labeled peptide nucleic acid (PNA) probe (Panagene Inc. catalog# F1006-5). The
denaturation took place at 85°C for 10 min and hybridization in dark at room temperature for
an hour. Post-hybridization washes with saline-sodium citrate/0.1% Tween-20 (pH 7.0; 2x10
min) at 55°C and at room temperature for 10 min were followed by nuclear counterstaining
with DAPI. The slides were imaged with a Zeiss Axio Imager epifluorescence microscope and
image acquisition took place through Hamamatsu Orca Flash 4.0 LT camera and Zen software.
The assessment of FISH slides was carried out independently by two authors (NM, MA).
ULMSs were classified as ALT-positive if5% of 300 assessed neoplastic cells displayed ALT-
associated, abnormally bright telomeric DNA aggregates. In all cases, regions of necrosis and
overlapping cells difficult to interpret were excluded from consideration.
Statistical analyses
Statistical analyses were performed using SPSS statistical software for Windows version 22.0
(SPSS Inc.). Here, survival was defined as overall survival time from the time of diagnosis. Sur-
vival curves related to TP53 and ATRX expression were generated using the Kaplan–Meier
method, and median survival times with 95% confidence intervals were given. Comparison of
survival curves between normal and aberrant expression was performed using the log-rank
test. P-value<0.05 was considered statistically significant. Association between TP53 and
ATRX expression statuses was evaluated using cross tabulation and Fisher’s exact test.
Supporting Information
S1 Fig. The types and positions of the observed TP53, ATRX, andMED12mutations.
(PDF)
S2 Fig. Representative images of TP53, ATRX, and DAXX immunohistochemistry, as well
as ALT phenotype in ULMSs. For TP53, heterogeneous expression of the protein was consid-
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